Founded in 2019, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address human genetic diseases (including many rare diseases) with high unmet needs. Their goal is to develop novel therapeutics for genetically associated kidney disorders, such as autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and Fabry disease.